The estimated Net Worth of Alan M Levine is at least $971 millier dollars as of 1 September 2024. Mr. Levine owns over 11,904 units of Axogen stock worth over $542,036 and over the last 5 years he sold AXGN stock worth over $0. In addition, he makes $429,375 as Independent Director at Axogen.
Alan has made over 4 trades of the Axogen stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 11,904 units of AXGN stock worth $158,085 on 1 September 2024.
The largest trade he's ever made was exercising 11,904 units of Axogen stock on 1 September 2024 worth over $158,085. On average, Alan trades about 2,757 units every 119 days since 2019. As of 1 September 2024 he still owns at least 40,816 units of Axogen stock.
You can see the complete history of Mr. Levine stock trades at the bottom of the page.
Alan M. Levine serves as Independent Director of the Company. Mr. Levine has served as a member of our Board of Directors since May 2019. Since February 2018, Mr. Levine has been the chairman, president, and chief executive officer of Ballad Health, an integrated health care delivery system. From January 2014 until January 2018, he served as the president and chief executive officer of Mountain States Health Alliance, the largest health system in upper east Tennessee and southwest Virginia. He served as a senior advisor to the Board of Directors, president of the Florida Group and corporate senior vice president during his July 2010 to January 2014 tenure at Health Management Associates, a hospital and health care facilities operator. From January 2008 until July 2010, Mr. Levine served as senior health policy advisor to Louisiana Governor Bobby Jindal, and as the Secretary of the Louisiana Department of Health and Hospitals on the Governor’s cabinet. He was the president and chief executive officer of the North Broward Hospital District, one of the largest public health and hospital systems in the nation, from July 2006 until January 2008. He also served as the secretary of the Florida Agency for Health Care Administration, the health planning and regulatory agency for the State of Florida with responsibility for the oversight of more than 30,000 health care facilities, and the $17 billion state Medicaid program, from June 2004 until July 2006. Mr. Levine served as the deputy chief of staff and senior health policy advisor to Governor Jeb Bush from January 2003 until June 2004. Alan holds an M.B.A., M.S. in Health Science, and B.S. in Health Education/Community Health from the University of Florida. He currently serves on the Board of Governors of the State University System of Florida, where he has served as chair of the Audit and Compliance Committee, chair of the Research and Academic Excellence, Committee and chair of the Select Committee on 2+2 Education Attainment.
As the Independent Director of Axogen, the total compensation of Alan Levine at Axogen is $429,375. There are 7 executives at Axogen getting paid more, with Eric Sandberg having the highest compensation of $1,113,440.
Alan Levine is 52, he's been the Independent Director of Axogen since 2019. There are 12 older and 2 younger executives at Axogen. The oldest executive at Axogen Inc. is Guido Neels, 71, who is the Independent Director.
Alan's mailing address filed with the SEC is C/O AXOGEN, INC. 13631 PROGRESS BLVD., SUITE 400, ALACHUA, FL, 32615.
Over the last 13 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels et Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: